Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A variant of TNFR2-Fc fusion protein exhibits improved efficacy in treating experimental rheumatoid arthritis.

PLoS computational biology - 5 Feb 2010

Yang Tong, Wang Zheng, Wu Fang, Tan Jingwei, Shen Yijun, Li Erguang, Dai Jingzhi, Shen Ronghai, Li Gang, Wu Jinsong, Wang Luochun, Wang Haibo, Liu Yanjun

Abstract excerpt

Etanercept, a TNF receptor 2-Fc fusion protein, is currently being used for the treatment of rheumatoid arthritis (RA). However, 25% to 38% of patients show no response which is suspected to be partially due to insufficient affinity of this protein to TNFalpha. By using computational protein desi...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arthritis, Experimental
Share to Cell Survival
Share to Etanercept

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histocytochemistry

Share to Immunoglobulin G

Share to Receptors, Tumor Necrosis Factor

Share to Surface Plasmon Resonance

Share to Tumor Necrosis Factor-alpha

Source

Open in PubMed Open full text

Identifiers

PMID: 20140191
DOI: 10.1371/journal.pcbi.1000669
PMCID: PMC2816690

Genes

SPR
TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20140191-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A variant of TNFR2-Fc fusion protein exhibits improved efficacy in treating experimental rheumatoid arthritis.PMID 20140191Read ↗

Fast binding kinetics and conserved 3D structure underlie the antagonistic activity of mutant TNF: useful information for designing artificial proteo-antagonists.Semantic proximity Read ↗

Computational design of variant TNF molecules: a novel methodology for inhibition of proinflammatory cascades.Semantic proximity Read ↗

Development and Characterization of a Potent Tumor Necrosis Factor-Alpha Blocking AgentSemantic proximity Read ↗

Novel protein engineering strategy for creating highly receptor-selective mutant TNFs.Semantic proximity Read ↗

A trimeric structural fusion of an antagonistic tumor necrosis factor-α mutant enhances molecular stability and enables facile modification.Semantic proximity Read ↗

Creation of an improved mutant TNF with TNFR1-selectivity and antagonistic activity by phage display technology.Semantic proximity Read ↗

Characterization of the neutralizing activity of three anti-human TNF monoclonal antibodies and prediction of their TNF epitopes by molecular modeling and mutant protein approach.Semantic proximity Read ↗

In Silico and In Vitro Investigations On Mutated IFNβ-scFv Against Human Collagen Type IISemantic proximity Read ↗

Development of potent humanized TNFα inhibitory nanobodies for therapeutic applications in TNFα-mediated diseasesSemantic proximity Read ↗

Insights into the binding recognition and computational design of IL-2 muteins with enhanced predicted binding affinity to the IL-2 receptor α.Semantic proximity Read ↗

Identification of tumor necrosis factor (TNF) amino acids crucial for binding to the murine p75 TNF receptor and construction of receptor-selective mutants.Semantic proximity Read ↗

Structural biology of tumor necrosis factor demonstrated for undergraduates instruction by computer simulation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.